

Anne J Novak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6178044/publications.pdf>

Version: 2024-02-01

124
papers

5,308
citations

147801

31
h-index

88630

70
g-index

125
all docs

125
docs citations

125
times ranked

8651
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 4322-4335.	7.0	2
2	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	5.2	2
3	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	7.2	28
4	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	1.3	3
5	Chronic lymphocytic leukemia B-cell-derived TNF± impairs bone marrow myelopoiesis. <i>IScience</i> , 2021, 24, 101994.	4.1	4
6	Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	6.2	27
7	Expression of KLRG1 and CD127 defines distinct CD8⁺ subsets that differentially impact patient outcome in follicular lymphoma. , 2021, 9, e002662.		16
8	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	1.4	0
9	T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3522-3522.	1.4	0
10	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	2.5	1
11	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1439-1439.	1.4	0
12	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	1.4	0
13	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	2.5	41
14	Impact of MYD88^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	4.1	33
15	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. <i>Clinical Cancer Research</i> , 2020, 26, 5759-5771.	7.0	5
16	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18
17	Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. <i>Redox Biology</i> , 2020, 36, 101657.	9.0	12
18	TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-“PD-1 Response in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5217-5231.	7.0	67

#	ARTICLE	IF	CITATIONS
19	Prognostic relevance of CD4+ T-cells in the microenvironment of newly diagnosed follicular lymphoma (FL) patients is independent of the tumor gene expression profile.. Journal of Clinical Oncology, 2020, 38, 8052-8052.	1.6	1
20	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	1.4	0
21	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	1.4	0
22	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. Blood, 2020, 136, 17-18.	1.4	0
23	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. Genetic Epidemiology, 2019, 43, 844-863.	1.3	28
24	SIRP α expression delineates subsets of intratumoral monocyte/macrophages with different functional and prognostic impact in follicular lymphoma. Blood Cancer Journal, 2019, 9, 84.	6.2	35
25	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
26	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	4.1	19
27	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Reports, 2019, 26, 2178-2193.e3.	6.4	57
28	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer Journal, 2019, 9, 22.	6.2	54
29	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
30	A Role for TNF- α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. Blood, 2019, 134, 4276-4276.	1.4	0
31	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Blood, 2019, 134, 2774-2774.	1.4	0
32	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. Blood, 2019, 134, 2764-2764.	1.4	0
33	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	1.4	0
34	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. Blood, 2019, 134, 923-923.	1.4	0
35	Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma. Blood, 2019, 134, 2790-2790.	1.4	0
36	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	30.7	1,224

#	ARTICLE	IF	CITATIONS
37	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	4.1	57
38	Soluble PD-1 ligands regulate T-cell function in Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018, 2, 1985-1997.	5.2	39
39	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	6.2	36
40	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	12.8	15
41	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20
42	Treatment Facility Volume and Outcomes in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	1.4	1
43	Depth of Response in Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	1.4	2
44	Immune System Profiling of Waldenström Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). <i>Blood</i> , 2018, 132, 4138-4138.	1.4	0
45	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenström Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	1.4	1
46	<i>FCGR3A</i> / <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
47	Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene. <i>Leukemia and Lymphoma</i> , 2017, 58, 2247-2250.	1.3	5
48	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	4.1	23
49	First report of <i>MYD88</i> ^{L265P} somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 42-43.	3.0	10
50	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	1.9	57
51	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
52	Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma. <i>Oncotarget</i> , 2017, 8, 61425-61439.	1.8	146
53	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016, 127, 2936-2938.	1.4	17
54	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	12.8	94

#	ARTICLE	IF	CITATIONS
55	Altered Expression of Immune Checkpoint Molecules Including Programmed Cell Death-1 (PD-1) and Its Ligands PD-L1/PD-L2 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1772-1772.	1.4	1
56	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	1.4	1
57	Signal-Regulatory Protein-1 (SIRP-1) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 2515-2515.	1.4	0
58	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	1.4	0
59	Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. <i>Blood</i> , 2016, 128, 4100-4100.	1.4	0
60	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	12.8	58
61	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070.	2.5	8
62	The Exhausted Intratumoral T Cell Population in B-Cell Non-Hodgkin Lymphoma Is Defined By LAG-3, PD-1 and tim-3 Expression. <i>Blood</i> , 2015, 126, 2661-2661.	1.4	7
63	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	1.4	0
64	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , 2014, 30, 3414-3416.	4.1	34
65	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	7.0	86
66	B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidylinositol 3-kinase pathway in lymphoma B cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 1884-1892.	1.3	6
67	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
68	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
69	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	4.1	43
70	An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data. <i>Journal of Clinical Oncology</i> , 2014, 32, e22171-e22171.	1.6	0
71	Presence and function of CD14+CD16-HLADR ^{low} monocytes in the peripheral blood of patients with T-cell non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2014, 32, e19539-e19539.	1.6	0
72	Interactions Between PD-1 and PD-L1 and PD-L2 Promote Malignant B-Cell Growth in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2013, 122, 4334-4334.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013, 122, 499-499.	1.4	2
74	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	1.4	1
75	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	7.1	853
76	IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. <i>Blood</i> , 2012, 120, 3774-3782.	1.4	40
77	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	4.1	37
78	MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression.. <i>Blood</i> , 2012, 120, 2699-2699.	1.4	3
79	Biologic Activity of STAT5A and STAT5B in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2012, 120, 2688-2688.	1.4	0
80	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	1.4	0
81	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	1.4	0
82	IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2012, 120, 1554-1554.	1.4	0
83	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	1.4	0
84	Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. <i>Blood</i> , 2011, 117, e190-e197.	1.4	40
85	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. <i>Blood</i> , 2011, 118, 5540-5549.	1.4	72
86	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570.	1.4	15
87	TGF- β 2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 1586-1586.	1.4	1
88	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	1.4	1
89	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 770-770.	1.4	0
90	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. <i>Blood</i> , 2011, 118, 2642-2642.	1.4	0

#	ARTICLE	IF	CITATIONS
91	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010, 207, 2569-2579.	8.5	96
92	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. <i>Blood</i> , 2010, 116, 1999-1999.	1.4	0
93	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	1.4	1
94	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010, 116, 468-468.	1.4	0
95	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. <i>Blood</i> , 2010, 116, 3115-3115.	1.4	0
96	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 143-143.	1.4	1
97	Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2009, 69, 4217-4224.	0.9	59
98	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. <i>Blood</i> , 2009, 113, 5206-5216.	1.4	46
99	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 925-925.	1.4	1
100	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3933-3933.	1.4	1
101	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 440-440.	1.4	4
102	Elevated Expression of GPR34 in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma and Its Association with Increased Cell Growth, Erk Activation, and AP-1 and CRE-Mediated Transcription.. <i>Blood</i> , 2009, 114, 3927-3927.	1.4	1
103	Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenström Macroglobulinemia.. <i>Blood</i> , 2009, 114, 1691-1691.	1.4	1
104	Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.. <i>Blood</i> , 2008, 112, 2251-2251.	1.4	3
105	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 603-603.	1.4	4
106	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25+ T cells. <i>Blood</i> , 2007, 110, 2537-2544.	1.4	181
107	Role of CCL5 and Interleukin-6 in the Biology of Waldenström Macroglobulinemia.. <i>Blood</i> , 2007, 110, 688-688.	1.4	2
108	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.. <i>Blood</i> , 2007, 110, 3585-3585.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 1347-1347.	1.4	0
110	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. Journal of Clinical Oncology, 2006, 24, 983-987.	1.6	85
111	Phase 1 Clinical Study of Atacept in Patients with Relapsed and Refractory B-Cell Lymphoma.. Blood, 2006, 108, 2722-2722.	1.4	1
112	Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25 ⁺ T Cells To Express Foxp3 and Gain Regulatory Function.. Blood, 2006, 108, 1724-1724.	1.4	17
113	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. Blood, 2005, 106, 2411-2411.	1.4	3
114	Role of B-Lymphocyte Stimulator (BLYS) in Waldenström's Macroglobulinemia.. Blood, 2005, 106, 601-601.	1.4	7
115	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. Blood, 2005, 106, 1495-1495.	1.4	6
116	Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma.. Blood, 2005, 106, 3312-3312.	1.4	0
117	Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL.. Blood, 2005, 106, 3311-3311.	1.4	0
118	Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood, 2004, 103, 689-694.	1.4	474
119	Expression of BLYS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood, 2004, 104, 2247-2253.	1.4	216
120	APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma.. Blood, 2004, 104, 2652-2652.	1.4	0
121	Elevated BLYS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLYS Polymorphisms.. Blood, 2004, 104, 964-964.	1.4	0
122	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. Blood, 2004, 104, 1397-1397.	1.4	0
123	B-Lymphocyte Stimulator (BLYS) Is Highly Expressed in Waldenström's Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	1.4	1
124	Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood, 2002, 100, 2973-2979.	1.4	213